These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 26037950)

  • 1. Varenicline and risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport accidents and offences: population based cohort study.
    Molero Y; Lichtenstein P; Zetterqvist J; Gumpert CH; Fazel S
    BMJ; 2015 Jun; 350():h2388. PubMed ID: 26037950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New Zealand.
    Harrison-Woolrych M; Ashton J
    Drug Saf; 2011 Sep; 34(9):763-72. PubMed ID: 21830838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis.
    Tonstad S; Davies S; Flammer M; Russ C; Hughes J
    Drug Saf; 2010 Apr; 33(4):289-301. PubMed ID: 20297861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study.
    Thomas KH; Martin RM; Davies NM; Metcalfe C; Windmeijer F; Gunnell D
    BMJ; 2013 Oct; 347():f5704. PubMed ID: 24124105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Lindson-Hawley N; Thomas KH; Fanshawe TR; Lancaster T
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD006103. PubMed ID: 27158893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of varenicline versus bupropion and risk of psychiatric adverse events.
    Pasternak B; Svanström H; Hviid A
    Addiction; 2013 Jul; 108(7):1336-43. PubMed ID: 23445269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropsychiatric events with varenicline: a modified prescription-event monitoring study in general practice in England.
    Buggy Y; Cornelius V; Fogg C; Kasliwal R; Layton D; Shakir SA
    Drug Saf; 2013 Jul; 36(7):521-31. PubMed ID: 23657823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2010 Dec; (12):CD006103. PubMed ID: 21154363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis.
    Thomas KH; Martin RM; Knipe DW; Higgins JP; Gunnell D
    BMJ; 2015 Mar; 350():h1109. PubMed ID: 25767129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2012 Apr; (4):CD006103. PubMed ID: 22513936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database.
    Gunnell D; Irvine D; Wise L; Davies C; Martin RM
    BMJ; 2009 Oct; 339():b3805. PubMed ID: 19797344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low incidence of adverse events following varenicline initiation among opioid dependent smokers with comorbid psychiatric illness.
    Nahvi S; Wu B; Richter KP; Bernstein SL; Arnsten JH
    Drug Alcohol Depend; 2013 Sep; 132(1-2):47-52. PubMed ID: 23332438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Varenicline, smoking cessation, and neuropsychiatric adverse events.
    Gibbons RD; Mann JJ
    Am J Psychiatry; 2013 Dec; 170(12):1460-7. PubMed ID: 24030388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New reports examine psychiatric risks of varenicline for smoking cessation.
    Kuehn BM
    JAMA; 2012 Jan; 307(2):129-30. PubMed ID: 22235073
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study.
    Kasliwal R; Wilton LV; Shakir SA
    Drug Saf; 2009; 32(6):499-507. PubMed ID: 19459717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2011 Feb; (2):CD006103. PubMed ID: 21328282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden.
    Molero Y; Larsson H; D'Onofrio BM; Sharp DJ; Fazel S
    BMJ; 2019 Jun; 365():l2147. PubMed ID: 31189556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial.
    Anthenelli RM; Morris C; Ramey TS; Dubrava SJ; Tsilkos K; Russ C; Yunis C
    Ann Intern Med; 2013 Sep; 159(6):390-400. PubMed ID: 24042367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropsychiatric adverse events of varenicline: a systematic review of published reports.
    Ahmed AI; Ali AN; Kramers C; Härmark LV; Burger DM; Verhoeven WM
    J Clin Psychopharmacol; 2013 Feb; 33(1):55-62. PubMed ID: 23277249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A preliminary benefit-risk assessment of varenicline in smoking cessation.
    Cahill K; Stead L; Lancaster T
    Drug Saf; 2009; 32(2):119-35. PubMed ID: 19236119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.